scholarly journals Euphorbia grandicornis Sap Keratouveitis: A Case Report

2016 ◽  
Vol 7 (1) ◽  
pp. 125-129
Author(s):  
María Gómez-Valcárcel ◽  
Graciana Fuentes-Páez
Keyword(s):  
Complete Resolution ◽  
Sesquiterpene Lactones ◽  
Sodium Hyaluronate ◽  
Conjunctival Hyperemia ◽  
Blurred Vision ◽  
Case Presentation ◽  
Corrected Visual Acuity ◽  
Dexamethasone Phosphate ◽  
Best Corrected Visual Acuity ◽  
Extraction Spectrophotometry

Purpose: To describe a case of keratouveitis caused by Euphorbia grandicornis sap, that resolved with topic steroids. Methods: We report a case presentation of a patient with keratouveitis. Results: A 70-year-old woman suffered from accidental ocular contact with E. grandicornis sap in her left eye. Two hours after the contact, she attended the clinic due to conjunctival hyperemia and pain. Best-corrected visual acuity (BCVA) was 20/25. The toxic conjunctivitis was treated with topical lubricant and steroid. After 24 h, she presented blurred vision. BCVA was 20/80. Toxic keratouveitis was diagnosed. Topical treatment with 1% cyclopentolate t.i.d., 5% sodium chloride, 1.14% dexamethasone phosphate each hour, and 4% sodium hyaluronate each hour was continued. Complete resolution was obtained 1 week later. Euphorbia sap content analysis was performed using dissolvent extraction spectrophotometry. Its contents included flavonoids, alkaloids, phenols and sesquiterpene lactones. Conclusion: Corneal exposure to E. grandicornis sap is a cause of nonvisually threatening keratouveitis when adequately treated with corticosteroids.

scholarly journals Corneal Perforation after Nd:YAG Capsulotomy: A Case Report and Literature Review

2019 ◽  
Vol 10 (1) ◽  
pp. 111-115 ◽  
Author(s):  
Maroun Khreish ◽  
Rana Hanna ◽  
Liron Berkovitz ◽  
Beatrice Tiosano
Keyword(s):  
Visual Acuity ◽  
Acute Onset ◽  
Systemic Scleroderma ◽  
Posterior Capsular Opacification ◽  
Corneal Perforation ◽  
Blurred Vision ◽  
Case Presentation ◽  
Corrected Visual Acuity ◽  
Nd:Yag Laser Capsulotomy ◽  
Corneal Laceration

Background: Nd:YAG capsulotomy is the treatment of choice for posterior capsular opacification after cataract surgery. We report a case of corneal perforation following Nd:YAG capsulotomy in a patient with systemic scleroderma. Case Presentation: A 69-year-old woman presented with acute onset of blurred vision 2 weeks following Nd:YAG laser capsulotomy for posterior subcapsular opacification. On examination, her best-corrected visual acuity was 1/120, and bio-microscopy revealed a central full-thickness corneal laceration. Conservative treatment consisted of topical ocular antibiotics, cycloplegics, hypotensive drops and a soft therapeutic contact lens. Her final visual acuity improved to 6/18 with resolution of the corneal laceration. Conclusion: The possibility of corneal perforation after Nd-YAG capsulotomy in patients with systemic scleroderma and connective tissue disease should be borne in mind when treating such patients.

scholarly journals Endophthalmitis Following Exposure of a Haptic After Sutureless Intrascleral Intraocular Lens Fixation

2018 ◽  
Vol 3 (1) ◽  
pp. 28-30 ◽  
Author(s):  
Shumpei Obata ◽  
Masashi Kakinoki ◽  
Yoshitsugu Saishin ◽  
Masahito Ohji
Keyword(s):  
Intraocular Lens ◽  
Ocular Pain ◽  
Conjunctival Hyperemia ◽  
Corrected Visual Acuity ◽  
Long Term Follow Up ◽  
White Substance ◽  
Iol Fixation ◽  
Best Corrected Visual Acuity

An 88-year-old woman who had undergone sutureless intrascleral fixation of the intraocular lens (IOL) 3 years previously was seen at an eye clinic because of ocular pain and loss of vision 2 days prior to this visit. She was diagnosed with endophthalmitis and referred to our hospital. At her first presentation here, the best-corrected visual acuity (BCVA) was 0.01 in the left eye, and conjunctival hyperemia and hypopyon were apparent. A haptic was exposed outside the conjunctiva at the nasal upper quadrant, with a white substance around the haptic. The fundus was not visible. We diagnosed endophthalmitis. That same day, we performed vitrectomy and IOL removal, immediately followed by intravitreal injection of antibiotic. The inflammation resolved gradually, and at the 1-year follow-up her BCVA had recovered to 0.6. Patients should receive careful, long-term follow-up after sutureless intrascleral IOL fixation.

scholarly journals Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy

2017 ◽  
Vol 8 (1) ◽  
pp. 271-278 ◽  
Author(s):  
Thomas Bertelmann ◽  
Hans Ulrich Frank ◽  
Hendrik Ansgar Fuchs ◽  
Nicolas Feltgen
Keyword(s):  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Retinal Thickness ◽  
Retrospective Case ◽  
Case Presentation ◽  
Vein Occlusion ◽  
Corrected Visual Acuity ◽  
Anti Vegf ◽  
Best Corrected Visual Acuity ◽  
Macular Ischemia

Purpose: To report a case with ischemic macular edema (ME) due to an acute branch retinal vein occlusion (BRVO) which was treated with repeated intravitreal anti-VEGF injections. Methods: Retrospective case presentation. Results: A 66-year-old female patient was treated with repeated intravitreal anti-VEGF injections due to ischemic ME following an acute BRVO. Over a period of 2.5 years best corrected visual acuity increased from 0.06 to 0.6 (decimal notation) accompanied by a reduction in central retinal thickness from 546 to 292 µm. Overall 17 anti-VEGF injections were administered to treat repeated recurrence of ME. Macular ischemia did not worsen during this profound intravitreal anti-VEGF therapy. Conclusion: Intravitreal anti-VEGF therapy can be a beneficial treatment strategy even in ischemic ME following an acute BRVO.

scholarly journals Reconstruction of Photoreceptor Outer Layers after Steroid Therapy in Solar Retinopathy

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Masaki Nakamura ◽  
Koji Komatsu ◽  
Satoshi Katagiri ◽  
Takaaki Hayashi ◽  
Tadashi Nakano
Keyword(s):  
Steroid Therapy ◽  
Clinical Course ◽  
Oral Prednisolone ◽  
Central Scotoma ◽  
Case Presentation ◽  
Ellipsoid Zone ◽  
Corrected Visual Acuity ◽  
Interdigitation Zone ◽  
The Right ◽  
Best Corrected Visual Acuity

Purpose. To report the clinical course of solar retinopathy after steroid therapy. Case Presentation. A 45-year-old male gazed at the sun and noticed bilateral central scotoma and decreased vision after the episode. After 7 weeks from onset, ophthalmic examinations were firstly performed. Decimal best corrected visual acuity (BCVA) was decreased to 0.8 and 0.7 in the right and left eyes. Funduscopy showed a tiny, yellowish spot in the fovea bilaterally. Corresponding to the lesion, optical coherence tomography (OCT) images showed an elevated and blurred ellipsoid zone and loss of the interdigitation zone. A posterior sub-Tenon triamcinolone injection in the right eye and oral prednisolone therapy were performed as a medication. BCVA was improved to 1.2 and 1.0 in the right and left eyes at 9 weeks after medication. OCT images showed ellipsoid zone was gradually improved bilaterally, which became nearly normal at 4 weeks in the right eye and at 21 weeks in the left eye. The loss of the interdigitation zone remained at 12 weeks in the right eye and at 21 weeks at the left eye. Conclusions. We described a case with solar retinopathy who exhibited anatomical recovery of the photoreceptor outer layers by steroid therapy, started after 7 weeks from onset.

scholarly journals Profile of Patients with Floaters in Saiful Anwar Hospital Malang

2018 ◽  
Vol 1 (2) ◽  
Author(s):  
Fenti Kusumawardhani Hidayah ◽  
Nadia Artha Dewi ◽  
Safaruddin Refa
Keyword(s):  
Posterior Vitreous Detachment ◽  
Descriptive Study ◽  
Posterior Uveitis ◽  
Posterior Segment ◽  
Retinal Break ◽  
Blurred Vision ◽  
Common Cause ◽  
Corrected Visual Acuity ◽  
Eye Examination ◽  
Best Corrected Visual Acuity

Introduction: To report the profile of patients with floaters as a subjective complain in Saiful Anwar Hospital from July 2012 until June 2013. Methods: an observasional descriptive study was conducted, collecting data on gender, age, subjective complain (floaters, flashes and subjective vision reduction), best corrected visual acuity and diagnose from patient’s medical record. Result: 169 patients (215 eyes) were included in this study. Female patients contributed a higher percentage than male with mean of age was 49 years old. The subjective complain was floaters (67%), floater with blurred vision (22%), floater with flashes (6%) and patients with floaters, flashes, and blurred vision was 5%. Myopia was the most common refraction problem. Diagnose recorded from this study were posterior vitreous detachment (PVD) (34%), no abnormalities (13%), PDR (10%), RRD (9%), peripheral retinal degeneration (14%) retinal break (6%), corpus vitreous degeneration (3%), vitreous haemorhage (3%), posterior uveitis (2%) and others (6%). Conclusion: The most common cause of floaters is PVD. Even it is usually a save condition but there are some condition with floater as a subjective complain which is threatening vision, so accurate eye examination from anterior to posterior segment were needed.

scholarly journals Severe sequelae in bilateral acute iris transillumination syndrome secondary to the use of oral moxifloxacin: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Nicolás Rivera-Valdivia ◽  
Karla Arteaga-Rivera ◽  
Juliana Reyes-Guanes ◽  
Natalia Neira-Segura ◽  
Alejandra de-la-Torre
Keyword(s):  
Bacterial Infections ◽  
Case Reports ◽  
Fourth Generation ◽  
Pigment Dispersion ◽  
Ocular Pain ◽  
Conjunctival Hyperemia ◽  
Blurred Vision ◽  
Case Presentation ◽  
Ahmed Valve ◽  
Valve Implantation

Abstract Background Moxifloxacin is a fourth-generation fluoroquinolone used as a second-line treatment for multiple bacterial infections. Uveitis has been described as an adverse effect related to this medication. Although several case reports have been published describing uveitis and bilateral acute iris transillumination syndrome related to moxifloxacin, we present a unique case of a patient with severe sequelae associated with bilateral acute iris transillumination syndrome secondary to the use of oral moxifloxacin. Case presentation A 45-year-old Colombian hispanic female presented bilateral conjunctival hyperemia, decreased visual acuity, blurred vision, photophobia, and ocular pain after 15 days of treatment with systemic moxifloxacin for an upper tract respiratory infection. The patient presented unilateral anterior chamber pigment dispersion, mydriatic and nonreactive pupils, extensive iris transillumination defects, and secondary glaucoma. Blood and aqueous humor tests were negative for infectious and autoimmune diseases. Moxifloxacin-induced bilateral acute iris transillumination syndrome was diagnosed. Permanent sequelae such as ocular pain, photophobia, and focus difficulty secondary to severe bilateral iridian atrophy and inability of synkinetic reflex were left. Additionally, glaucoma was diagnosed, and Ahmed valve implantation was required. Conclusions We should be aware of the possible association between moxifloxacin and bilateral acute iris transillumination syndrome. A detailed anamnesis, adequate examination, and laboratory tests are necessary to reach an early diagnosis and treatment to avoid unnecessary therapies. Larger studies should be carried out to understand the pathophysiology, diagnosis, management, and sequelae of the disease.

scholarly journals Corneal Toxicity Following Exposure to Asclepias Tuberosa

2017 ◽  
Vol 11 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Lauge Hjorth Mikkelsen ◽  
Hassan Hamoudi ◽  
Cigdem Altuntas Gül ◽  
Steffen Heegaard
Keyword(s):  
Visual Acuity ◽  
Differential Diagnosis ◽  
Corneal Endothelium ◽  
Rare Case ◽  
Corneal Oedema ◽  
Blurred Vision ◽  
Corrected Visual Acuity ◽  
Corneal Toxicity ◽  
Best Corrected Visual Acuity ◽  
Plant Latex

Purpose: To present a case of corneal toxicity following exposure to milky plant latex from Asclepias tuberosa. Methods: A 70-year-old female presented with blurred vision and pain in her left eye after handling an Ascepias tuberosa. Clinical examination revealed a corneal stromal oedema with small epithelial defects. The corneal endothelium was intact and folds in Descemets membrane were observed. The oedema was treated with chloramphenicol, dexamethasone and scopolamine. Results: The corneal oedema had appeared after corneal exposure to the plant, Asclepias tuberosa, whose latex contains cardenolides that inhibit the Na+/ K+-ATPase in the corneal endothelium. The oedema resolved after 96 hours. After nine months the best corrected visual acuity was 20/20. Conclusion: Corneal toxicity has previously been reported for plants of the Asclepias family. This is a rare case describing severe corneal toxicity caused by exposure to latex from Asclepias tuberosa. Handling of plants of the Asclepias family should be kept as a differential diagnosis in cases of acute corneal toxicity.

scholarly journals Macular Hole Progression following Ocriplasmin Intravitreal Injection

2014 ◽  
Vol 2014 ◽  
pp. 1-2 ◽  
Author(s):  
Edward Casswell ◽  
Guillermo Fernandez-Sanz ◽  
Danny Mitry ◽  
Sheila Luk ◽  
Rahila Zakir
Keyword(s):  
Optical Coherence Tomography ◽  
Visual Acuity ◽  
Intravitreal Injection ◽  
Macular Hole ◽  
Optical Coherence ◽  
Vitreomacular Adhesion ◽  
Blurred Vision ◽  
Corrected Visual Acuity ◽  
Best Corrected Visual Acuity

Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she subsequently underwent a left intravitreal ocriplasmin injection. One week after the injection, VMA had been released but with enlargement of the macular hole and a drop in her BCVA to 6/60. This persisted at 1 month after the injection. It is important to warn patients that ocriplasmin may lead to an enlargement of their macular hole with resultant loss in visual acuity.

scholarly journals Treatment of Symptomatic Vitreomacular Adhesion with Expansile Sulfur Hexafluoride (SF6) Gas

2017 ◽  
Vol 11 (1) ◽  
pp. 80-83 ◽  
Author(s):  
Dominic M Buzzacco ◽  
Sugat S Patel
Keyword(s):  
Visual Acuity ◽  
Intravitreal Injection ◽  
Complete Resolution ◽  
Sulfur Hexafluoride ◽  
Low Cost ◽  
Vitreomacular Adhesion ◽  
Corrected Visual Acuity ◽  
Wide Availability ◽  
Partial Release ◽  
Best Corrected Visual Acuity

Background: To evaluate intravitreal injection of expansile sulfur hexafluoride (SF6) as a low cost and effective treatment for symptomatic vitreomacular adhesion (sVMA). Methods: Retrospective analysis of all patients with sVMA treated with pneumatic vitreolysis using SF6 gas presenting to a clinical practice from January 2005 and June 2013. Results: Six cases were included in the study. Five patients (83%) experienced complete resolution of the vitreomacular adhesion. One patient had a partial release of the vitreomacular adhesion. Four patients (67%) had a one line improvement in best corrected visual acuity. Conclusion: Due to its low cost, wide availability, and apparent efficacy, intravitreal injection of expansile SF6 should be investigated further as a possible treatment modality for sVMA.

scholarly journals Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy

2021 ◽  
Vol 10 (24) ◽  
pp. 5739
Author(s):  
Young-Joon Jeon ◽  
Jae-Hui Kim ◽  
Jong-Woo Kim ◽  
Chul-Gu Kim
Keyword(s):  
Polypoidal Choroidal Vasculopathy ◽  
Complete Resolution ◽  
Retinal Thickness ◽  
Treatment Options ◽  
Short Term ◽  
Corrected Visual Acuity ◽  
Before And After ◽  
The Mean ◽  
Choroidal Vasculopathy ◽  
Best Corrected Visual Acuity

Background: To evaluate the short-term outcomes of switching to ranibizumab in aflibercept-resistant polypoidal choroidal vasculopathy (PCV). Methods: This retrospective study included 18 eyes diagnosed with aflibercept-resistant PCV. All patients were treated with two to four consecutive ranibizumab injections at 4–5-week intervals. The best-corrected visual acuity (BCVA), and central retinal thickness (CRT) values before and after switching to ranibizumab were compared. The proportion of eyes showing ≥100 µm decrease in retinal thickness and/or complete resolution of fluid after switching was identified. Results: The mean number of aflibercept injections before switching was 5.7 ± 3.3. After switching, a mean of 2.8 ± 0.6 consecutive ranibizumab injections was performed. The mean logarithm of minimal angle of resolution (logMAR) BCVA was 0.41 ± 0.26 (Snellen equivalents = 20/51) before switching, and 0.40 ± 0.30 (20/50) after switching (p = 0.574). The mean CRT was 422.2 ± 152.4 µm before switching, and 400.7 ± 182.0 µm after switching (p = 0.236). A decrease in CRT of ≥100 µm, and/or complete resolution of fluid was noted in three eyes (16.7%). Conclusions: Switching to ranibizumab in aflibercept-resistant polypoidal choroidal vasculopathy was not effective in most patients, suggesting the need for further investigation to seek more effective treatment options for this condition.

Sign in / Sign up

Export Citation Format

Share Document